While drug combination therapies are a well-established concept in cancer treatment, identifying novel synergistic combinations is challenging due to the size of combinatorial space. However, computational approaches have emerged as a time- and cost-efficient way to prioritize combinations to test, based on recently available large-scale combination screening data. Recently, Deep Learning has had an impact in many research areas by achieving new state-of-the-art model performance. However, Deep Learning has not yet been applied to drug synergy prediction, which is the approach we present here, termed DeepSynergy. DeepSynergy uses chemical and genomic information as input information, a normalisation strategy to account for input data heterogeneity, and conical layers for modelling. DeepSynergy significantly outperformed other machine learning methods like Gradient Boosted Trees, Random Forests, Support Vector Machines, and Elastic Nets on this large publicly available synergy data set based on the MSE, which is an improvement by 7.2% over the second best method. The mean Pearson correlation coefficient between the measured and the predicted values of DeepSynergy is 0.73. Applying DeepSynergy for classification resulted in an AUC of 0.90.
Example code for data normalization and a cross validation run is provided.
Data for the example code as well as all labels and SMILES for the compounds are provided on:
The predictions of DeepSynergy are provided via a webservice:
If you used our work and found the provided data helpful please cite:
K Preuer, RPI Lewis, S Hochreiter, A Bender, KC Bulusu, G Klambauer. 2017. DeepSynergy: predicting anti-cancer drug synergy with Deep Learning. Bioinformatics. btx806